Enanta Pharmaceuticals
Great Chemistry Cures

Molecular Basis for the Antiviral Action of EDP-235: A Potent and Selective SARS-CoV-2 3CLpro Inhibitor

Anand Balakrishnan

2022 Annual Meeting of ASBMB
April 4th, 2022

SARS-CoV-2 life cycle and enzyme targets for antiviral development



Catalytic cycle of 3C-like protease from SARS-CoV-2

3CLpro Consensus Site





Catalytic activity monitored with FRET [fluorescence resonance energy transfer] assay

EDP-235 is a highly potent 3CLpro inhibitor and retains activity against SARS-CoV-2 variants

- 3CLpro is highly conserved across SARS-CoV-2 variants
- All variant enzymes were active in protease biochemical assays



3CLpro Enzyme Assay			
SARS-CoV-2 Lineage	WHO Classification	3CLpro Mutation	EDP-235 IC_{50} (nM)
A	n/a	-	5.8 ± 3.7
B.1.351	Beta	K90R	2.8 ± 0.9
B.1.351.2	Beta	K90R/A193V	5.4 ± 1.0
P.2	Zeta	L205V	3.4 ± 1.0
B.1.617.3	n/a	A194S	5.7 ± 0.5
B.1.1.318	n/a	T21I	2.0 ± 0.1
C.36.3, C.37	n/a	G15S	4.7 ± 2.5
B.1.1.529	Omicron	P132H	4.1 ± 0.8

Live Virus			
SARS-CoV-2 Lineage	WHO Classification	3CLpro Mutation	EDP-235 EC_{50} (nM)
A	n/a	-	5.1
B.1.617.2	Delta	-	4.3
B.1.1.529	Omicron	P132H	7.3

IC_{50} = half-maximal inhibitory concentration. *The 3CLpro sequences for the ancestral A lineage and B.1.617.2 (Delta) variant are identical. Antiviral activity determined in the presence of a p-glycoprotein inhibitor.

EDP-235 is a tight-binding inhibitor of SARS-CoV-2 3CLpro

Experimental Setup



1. Incubate at RT for 30 minutes
2. Add substrate
3. Kinetic readout over 1 hour

RT = room temparture

IC_{50} vs. 3CLpro Concentration



The IC_{50} of EDP-235 increases linearly with increasing 3CLpro

$$IC_{50} = 0.5*[3CLpro] + K_i^{app}$$

Morrison Fit Analysis for K_i^{app}



$$K_i^{app} = 0.1 \pm 0.06 \text{ nM}$$

EDP-235 is a time-dependent inhibitor of SARS-CoV-2 3CLpro

Progress curves



Slow onset of inhibition

k_{obs} vs. EDP-235 concentration



One-step reversible model

Velocity vs. EDP-235 concentration



v_s decreases with [EDP-235]

Parameter	Value Mean ± SD, n=3
k_{on}	(2.6 ± 1.6) x 10^5 $M^{-1}s^{-1}$
k_{off}	(9 ± 1) x 10^{-4} s^{-1}
K_i^{app}	4.7 ± 2.4 nM

~ k_{cat}/K_m = 2.1 x10^5 $M^{-1}s^{-1}$

Antimicrobial Agents and Chemotherapy (2021). 65(4):e03577-20

EDP-235 is a reversible inhibitor of SARS-CoV-2 3CLpro

Experimental Setup

Preincubate enzyme with inhibitor

Rapid dilution into substrate solution



1. 3CLpro (5 µM)
2. EDP-235 (0, 5, 10, 50 µM)
3. 2 h at RT to form EI complex

Dilution Phase and Recovery of Activity



RT = room temparture
E = Enzyme
I = Inhibitor

$$EI \underset{k_{on}}{\overset{k_{off}}{\rightleftharpoons}} E + I$$

$k_{obs} = (8.7 \pm 2.6) \times 10^{-4}\ s^{-1}$

corresponds to residence time ~ 19 min

EDP-235 is a substrate competitive inhibitor of SARS-CoV-2 3CLpro

Kinetic Analysis with Respect to Substrate



EDP-235 is a competitive inhibitor with respect to the FRET peptide substrate

Summary of Kinetic Mechanism Characterization

Parameter	Value
IC_{50}	5.8 nM
K_i	3.0 ± 1.6 nM
k_{on}	(2.6 ± 1.6) x 10^5 $M^{-1}s^{-1}$
k_{off}	(8.7 ± 2.6) x10^{-4} s^{-1}
Residence time	~ 19 min
Kinetic Mechanism	Time-dependent, reversible, Substrate competitive inhibition

EDP-235 analog binds at the active site of SARS-CoV-2 3CLpro

Quarternary structure of SARS-CoV-2 3CLpro dimer



Compound binding site with key residues



- Crystal structures of apo 3CLpro and co-structures of key compounds were obtained at 2.5-2.8 Å.
- 3CLpro crystallized as a dimer and active site residues make essential polar contacts with compounds.
- Structures provide support for mechanism of inhibition of EDP-235.

EDP-235 shows antiviral activity against all human coronaviruses

Virus	3CLpro Enzyme Assay IC_{50} (nM)	Live Virus Assay				
		Cell Type	Endpoint	EC_{50} (nM)	CC_{50} (nM)	SI
SARS-CoV-2	**5.8**	Vero E6*	CPE	**5.1**	>10,000	>1,960
HCoV-229E	**5.4**	MRC-5	CPE	**3.6**	>50,000	>13,889
HCoV-HKU1	**3.8**	-	-	-	-	-
HCoV-NL63	**1.8**	LLC-MK2	RT-qPCR	**6.1**	-	-
HCoV-OC43	**3.4**	HCT-8*	RT-qPCR	**56**	-	-
SARS-CoV	**1.9**	Vero E6*	CPE	**24**	>3,000	>125
MERS-CoV	**70**	Vero 76	CPE	**150**	>26,000	>173
			Viral Yield	**130 [EC_{90}]**	>26,000	>200

*Assay performed in the presence of a P-glycoprotein inhibitor (CP-100356, 2 μM) to prevent transporter-mediated efflux. CPE = cytopathic effect; P-gpi = P-glycoprotein inhibitor CP-100356 (2 μM); qPCR = quantitative polymerase chain reaction. HCoV-229E, HCoV-HKU1, HCoV-OC43, HCoV-NL63 = human coronavirus 229E, HKU1, OC43, and NL63, respectively; SARS-CoV = severe acute respiratory syndrome; MERS-CoV = Middle East respiratory syndrome. Vero 76 and Vero E6 cells are derived from African green monkey kidney epithelia, MRC-5 are human lung fibroblasts, HCT-8 are derived from a human ileocecal adenocarcinoma, and LLC-MK2 are Rhesus monkey epithelial cells. pHAEC = primary human airway epithelial cells.

EDP-235 shows highly selective inhibition of 3CLpro compared to human proteases

Cysteine Proteases
- SARS CoV 2 – PLpro, 3CLpro
- Caspases 1 – 11, 14
- Cathepsins B, C, D, E, G, H, K, L, S, V
- Papain, Calpain 1

Serine Proteases
- Trypsin
- TMPRSS 2
- Furin

Aspartyl protease
- BACE1

Zn metalloprotease
- ACE 1, 2

- Tested against 31 host proteases of diverse classes
- IC_{50} > 100 µM against 23 out of 31 including host proteases relevant to viral infection

Target	EDP-235 IC_{50} (µM)
Caspase 2	4.6
Caspase 3	4.2
Caspase 6	2
Caspase 7	4.7
Caspase 8	22.5
Caspase 9	4.7
Caspase 14	9
Cathepsin K	18.5
SARS-CoV-2 3CLpro	0.0058
Selectivity Index	**> 340**

Cysteine Proteases

Host proteases in viral entry/fusion



- ACE 2
- Cathepsin B
- Cathepsin L
- Trypsin
- TMPRSS 2
- Furin

1. *Signal Transduction and Targeted Therapy* (2021). 6:233
2. *Int. J. Mol. Sci.* (2020), 21(24), 9523

Molecular mechanism of EDP-235 action and its pharmacological effect

Molecular Observations	*In vitro* Pharmacology
Time-dependence/on-target residence time	High potency and antiviral efficacy
Substrate competitive /active site binder	Broad spectrum anti-coronaviral
Strong interactions with highly conserved active-site residues	High barrier to resistance
High degree of selectivity over other mammalian proteases	On target pharmacology and low off-target effects

Preclinical Properties		EDP-235[1]
Mechanism		**Protease Inhibitor**
Potency	Enzyme IC_{50} (nM)	**5.8**
	Vero Cell EC_{50} (nM)	**5.1**
Oral Bioavailability[2]		**95%**
Lung/Plasma ratio[3]		**4.1**
Projected Efficacious Dose		**100 – 500mg QD**

1. Jiang *et al.*, ISIRV Poster #120, Oct 19, 2021
2. Oral bioavailability in rats for EDP-235
3. AUC lung to plasma ratio in rats for EDP-235

Acknowledgements

Virology

Archie Reyes

Nalini Bisht

Joyce Sweeney

Rachel Levene

Nicole McAllister

Tessa Cressey

Nathan Manalo

Miranda Crepeau

Michael Rhodin

Michael Vaine

Bryan Goodwin

Medicinal Chemistry

Ruichao Shen

Guoqiang Wang

Joe Panarese

Yat Sun Or

DMPK

Shucha Zhang

Lijuan Jiang

Program Management

Manami Shizuka

Toxicology

Kellye Daniels

Enanta
Pharmaceuticals

www.enanta.com